Calprotectin and Ischemia Modified Albumin Serum to Measure Disease Activity in Behçet's Disease

Study Overview
=================
Brief Summary
-----------------
Behçet's Disease activity was evaluated using BD Current Activity Form (BDCAF). Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.

Official Title
-----------------
Evaluation of Calprotectin and Ischemia Modified Albumin Serum Levels as Biomarkers to Measure Disease Activity in Behçet's Disease

Conditions
-----------------
Behçet's Diseasecases

Intervention / Treatment
-----------------
* Diagnostic Test: Serum calprotectin and IMA concentrations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: new case of Behçet's disease available medical record Well known duration of BD, Well known current treatment used Well known current organ involvement Exclusion Criteria: concomitant autoimmune or auto-inflammatory disorder; acute or chronic infections; cancer; diabetes; heart failure; gestation or up to six months after birth

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br> | Diagnostic Test: Serum calprotectin and IMA concentrations<br>* Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.<br>|
| control<br> | Diagnostic Test: Serum calprotectin and IMA concentrations<br>* Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BD activity was evaluated using BD Current Activity Form (BDCAF). | BD activity was assessed with BDCAF which assesse clinical characteristics present during the previous one month before evaluation. BDCAF include the following components: headaches; mouth ulcers; erythema; genital ulcers; arthritis; arthralgia; nausea/emesis/pain in abdomen; rectal bleeding; diarrhea; and new ocular, vascular, and nervous symptoms. Each component takes a score of (0) if absent or (1) if present [30]. The total BDCAF score was calculated by adding up the positive components (maximum score = 12). A BDCAF patient index score ≥2 was considered as active BD, while a score less than 2 was considered as inactive BD | 3 years | 
| Serum calprotectin concentrations | Blood samples were withdrawn from all participants 12 h after fasting. Samples underwent centrifugation at 4000 rpm for ten minutes. The sera were collected and kept at -80°C till analysis. Serum calprotectin concentrations were quantified utilizing a commercial calprotectin ELISA kit (Hycult Biotech Inc, US) based on manufacturer's instructions. Levels of high-sensitivity CRP (hsCRP) and albumin were detected using the immunoturbidimetric technique. Unit of measurment (μg/ml ) | 3 years | 
| Ischaemia Modified Albumin (IMA) serum concentrations | IMA was quantified based on albumin cobalt binding colorimetric assay according to Bar-Or and colleagues and the levels were expressed in absorbance units (ABSU). To obtain corrected IMA values, the equation (individual albumin level/median albumin level of population) × IMA ABSU value was applied. Unit of measurment ( kU/L) | 3 years |